Company Overview and News

0
Domino’s Pizza boss in the dough with $36.8m payday

9h theage.com.au
Domino's Pizza boss Don Meij has topped the table of Australia's highest-paid chief executive, taking home $36.8 million, which is almost 435 times the full-time average wage.
MQBKY MCQEF MQG

0
Domino’s Pizza boss in the dough with $36.8m payday

9h smh.com.au
Domino's Pizza boss Don Meij has topped the table of Australia's highest-paid chief executive, taking home $36.8 million, which is almost 435 times the full-time average wage.
MQBKY MCQEF MQG

0
Domino’s Pizza boss in the dough with $38.8m payday

10h theage.com.au
Domino's Pizza boss Don Meij has topped the table of Australia's highest-paid chief executive, taking home $38.8 million, which is almost 435 times the full-time average wage.
MQBKY MCQEF MQG

0
Domino’s Pizza boss in the dough with $38.8m payday

10h smh.com.au
Domino's Pizza boss Don Meij has topped the table of Australia's highest-paid chief executive, taking home $38.8 million, which is almost 435 times the full-time average wage.
MQBKY MCQEF MQG

0
CEO pay deals surge to 'highest level in 17 years'

10h abc.net.au
Chief executive pay hit record highs over the past year as wages growth for workers continues to flatline and trust in big business ebbs amid fallout from the banking royal commission.
MQBKY MCQEF MQG

5
EU mergers and takeovers (July 16)

14h reuters
BRUSSELS, July 16 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
AWI 39IB MQBKY RIO LGEPF RIO XOM HOGGF MCQEF DTEGF RTPPF LGEAF RIO TOT RTNTF SSUMF LGLD HRG MQG LGEJY DTEGY LGEIY

0
Oz CEO pay hits an all time high - Domino's boss gets the most dough

17h nzherald.co.nz
The pay of Australia's top listed company executives has hit a record high with the average rising 12 per cent in the last year to A$4.36m ($4.78m).
MQBKY MCQEF MQG

9
Wall Street Competes With Unregulated Banks for the Riskiest Loans - Bloomberg

2018-07-12 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
NMR MQBKY DB DGLD GS.PRB GS.PRA CS GS UGLD GLSSP 8604 NRSCF JEF MQG JBK DSLV VIIX GSC GS.PRICL CSSLF VIIZ TFG MCQEF GSJ GS.PRJ GS.PRI CSGKF N33 GS.PRD GS.PRC ZIV USLV GJS TVIX GS.PRN GS.PRK XIV

0
Only one chair will fit David Gonski as he joins Sydney Airports board

2018-07-12 theage.com.au
When someone as high profile as David Gonski joins a board like Sydney Airports you can bet your house that he has already been lined up for the big chair.
MQBKY SYD MOC MCQEF MQG SYDDF

0
Only one chair will fit David Gonski as he joins Sydney Airports board

2018-07-12 smh.com.au
When someone as high profile as David Gonski joins a board like Sydney Airports you can bet your house that he has already been lined up for the big chair.
MQBKY SYD MOC MCQEF MQG SYDDF

0
FOREX-Dollar strengthens against yen, EM rallies as trade fears wane

2018-07-10 reuters
NEW YORK, July 10 (Reuters) - The U.S. dollar rose to near a six-month high against the safe-haven Japanese yen on Tuesday and emerging market currencies like the Mexican peso, Brazilian real and Russian rouble also rose as global economic momentum appeared so far unscathed by trade tensions, prompting investors to buy riskier assets.
BNPZY MQBKY BNPQY BNPQF MCQEF MQG

5
EU mergers and takeovers (July 10)

2018-07-10 reuters
BRUSSELS, July 10 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
AWI 39IB MQBKY RIO LGEPF RIO XOM HOGGF MCQEF DTEGF RTPPF LGEAF RIO TOT RTNTF SSUMF LGLD HRG MQG LGEJY DTEGY LGEIY

4
FOREX-Dollar nears six-month high against yen as risk appetite returns

2018-07-10 reuters
NEW YORK (Reuters) - The dollar neared a six-month high against the safe-haven Japanese yen on Tuesday as investors bought riskier assets, encouraged by signs that trade tensions have yet to hurt economic momentum.
WFC WFCNP WFC.WS MQBKY WFC.PRL WFC.PRJ MCQEF WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX MQG WFC.PRW WFC.PRV

5
MOVES-Macquarie appoints three new members to commodities group

2018-07-10 reuters
July 10 (Reuters) - Australian investment bank Macquarie Group Ltd said it appointed three senior contributors to its cash equities business within the commodities and global markets group.
MQBKY C.WSA C C.PRL C.PRJ C.PRK C.PRG MCQEF C.PRC C.WS.B C.PRPCL CGBBW C.WS.A C.PRP C.PRU MQG C.PRS

0
UK’s ageing nuclear fleet offers target for China’s atomic tech

2018-07-10 thestar.com.my
HONG KONG: The possible replacement of the UK’s ageing nuclear reactor fleet may offer China’s ambitious atomic power companies an outlet for investment and technology.
MQBKY DSECF 8601 DSEEY MCQEF MQG

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

22m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

1h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...